文献速递产科母胎医学

新型抗磷脂抗体与不良妊娠结局之间的关联

Association Between Novel Antiphospholipid Antibodies and Adverse Pregnancy Outcomes.
PubMed 文献 · Obstet Gynecol · 2024-09-19

基于PROMISSE前瞻性队列(265例,含抗磷脂抗体伴或不伴系统性红斑狼疮及单纯系统性红斑狼疮孕妇),检测孕18周前血清抗β2糖蛋白I结构域1抗体(aD1)和抗磷脂酰丝氨酸-凝血酶原抗体。不良妊娠结局发生率为17.0%;aD1和抗磷脂酰丝氨酸-凝血酶原IgG是不良妊娠结局的显著独立预测因子,且与狼疮抗凝物强相关,联合使用可识别高危患者。

要点

  • aD1和抗磷脂酰丝氨酸-凝血酶原IgG是不良妊娠结局的独立预测因子。
  • 狼疮抗凝物、aD1和抗磷脂酰丝氨酸-凝血酶原IgG三者均阳性时不良妊娠结局率最高(47.6%)。
  • aD1或抗磷脂酰丝氨酸-凝血酶原IgG阳性与狼疮抗凝物阳性相关,两者均阳性时OR为27.9。

核心结论

  • 在伴或不伴系统性红斑狼疮的抗磷脂抗体阳性孕妇中,aD1和抗磷脂酰丝氨酸-凝血酶原IgG是不良妊娠结局的显著独立预测因子,并与狼疮抗凝物强相关。
  • 联合使用aD1和抗磷脂酰丝氨酸-凝血酶原IgG可能识别严重产科并发症风险最高的患者。

研究设计与样本

  • 数据来自PROMISSE前瞻性队列研究(NCT00198068),纳入抗磷脂抗体阳性孕妇(伴系统性红斑狼疮n=59或不伴系统性红斑狼疮n=106)及不伴抗磷脂抗体的系统性红斑狼疮孕妇(n=100),共265例。
  • 于孕龄小于18周时采集血清,分别用QUANTA Flash和QUANTA Lite系统定量aD1和抗磷脂酰丝氨酸-凝血酶原抗体水平。
  • 不良妊娠结局定义为:因子痫前期或胎盘功能不全于孕34周前分娩,或孕12周后胎死宫内。
  • 采用受试者工作特征(ROC)分析评估aD1和抗磷脂酰丝氨酸-凝血酶原抗体对不良妊娠结局的诊断性能,并进行双变量比较、多变量回归建模(后退法选择变量)及狼疮抗凝物与aD1和抗磷脂酰丝氨酸-凝血酶原抗体的逻辑回归分析。
  • 按狼疮抗凝物、aD1和抗磷脂酰丝氨酸-凝血酶原免疫球蛋白G(IgG)联合结果描述不良妊娠结局发生率。

主要发现

  • 265例中45例(17.0%)发生不良妊娠结局。
  • ROC曲线下面积:aD1为0.734(95%CI,0.664-0.805),抗磷脂酰丝氨酸-凝血酶原IgG为0.83(95%CI,0.751-0.899),抗磷脂酰丝氨酸-凝血酶原免疫球蛋白M(IgM)为0.612(95%CI,0.520-0.703)。
  • 与不良妊娠结局相关的标志物包括:aD1(P<.001)、抗心磷脂IgG(P<.001)、β2糖蛋白I IgG(P=.003)、抗磷脂酰丝氨酸-凝血酶原IgG(P<.001)、抗磷脂酰丝氨酸-凝血酶原IgM(P=.03)和狼疮抗凝物(P<.001)。
  • 后退法筛选出狼疮抗凝物、aD1和抗磷脂酰丝氨酸-凝血酶原IgG进入最终不良妊娠结局模型:狼疮抗凝物比值比(OR)7.0(95%CI,3.4-14.4),aD1 OR 12.1(95%CI,3.64-40.2),抗磷脂酰丝氨酸-凝血酶原IgG OR 11.4(95%CI,5.2-25.2)。
  • 从模型中移除狼疮抗凝物后,aD1和抗磷脂酰丝氨酸-凝血酶原IgG仍保持显著;aD1或抗磷脂酰丝氨酸-凝血酶原IgG的似然比小于0.1,二者在排除不良妊娠结局方面表现良好。

关键数值与推荐

  • 不良妊娠结局定义:因子痫前期或胎盘功能不全于孕34周前分娩,或孕12周后胎死宫内。
  • ROC曲线下面积:aD1 0.734(95%CI,0.664-0.805),抗磷脂酰丝氨酸-凝血酶原IgG 0.83(95%CI,0.751-0.899),抗磷脂酰丝氨酸-凝血酶原IgM 0.612(95%CI,0.520-0.703)。
  • 最终模型OR:狼疮抗凝物7.0(95%CI,3.4-14.4),aD1 12.1(95%CI,3.64-40.2),抗磷脂酰丝氨酸-凝血酶原IgG 11.4(95%CI,5.2-25.2)。
  • aD1和抗磷脂酰丝氨酸-凝血酶原IgG均阳性与狼疮抗凝物阳性的OR为27.9(95%CI,12.1-64.0)。
  • 狼疮抗凝物、aD1和抗磷脂酰丝氨酸-凝血酶原IgG均阳性者不良妊娠结局发生率最高(47.6%)。

临床怎么用

  • 在抗磷脂抗体阳性孕妇中,检测aD1和抗磷脂酰丝氨酸-凝血酶原IgG有助于识别不良妊娠结局高危患者。
  • aD1或抗磷脂酰丝氨酸-凝血酶原IgG似然比小于0.1,在排除不良妊娠结局方面表现良好。
  • 联合狼疮抗凝物、aD1和抗磷脂酰丝氨酸-凝血酶原IgG结果可能识别严重产科并发症风险最高的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the value of anti-β2 glycoprotein-I domain 1 (aD1) and antiphosphatidylserine-prothrombin antibodies for predicting adverse pregnancy outcomes in an at-risk population and to describe the relationship among aD1, antiphosphatidylserine-prothrombin, lupus anticoagulant, and other antiphospholipid antibodies (aPL). METHODS: Data were obtained from a prospective cohort of pregnant patients with aPL, with systemic lupus erythematosus (SLE) (n=59) or without SLE (n=106), or SLE without aPL (n=100) (PROMISSE [Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus and Antiphospholipid Syndrome] study; NCT00198068). Levels of aD1 and antiphosphatidylserine-prothrombin were quantified with the QUANTA Flash and QUANTA Lite systems, respectively, in sera collected at less than 18 weeks of gestation. Adverse pregnancy outcome was defined as delivery at before 34 weeks of gestation for preeclampsia or placental insufficiency or fetal death after 12 weeks of gestation. Receiver operating characteristic (ROC) analysis assessed the diagnostic properties of aD1 and antiphosphatidylserine-prothrombin for adverse pregnancy outcomes. Bivariate comparisons were made between each biomarker. Multivariable regression modeling of adverse pregnancy outcomes was performed, and backward selection determined variables for a final model for adverse pregnancy outcomes. Logistic regression of lupus anticoagulant quantified the association with aD1 and antiphosphatidylserine-prothrombin. The rate of adverse pregnancy outcomes was described by combined results of lupus anticoagulant, aD1, and antiphosphatidylserine-prothrombin immunoglobulin G (IgG). RESULTS: Of 265 individuals, 45 (17.0%) experienced adverse pregnancy outcomes. Area under the curve from ROC analysis for aD1 was 0.734 (95% CI, 0.664-0.805), for antiphosphatidylserine-prothrombin IgG was 0.83 (95% CI, 0.751-0.899), and for antiphosphatidylserine-prothrombin immunoglobulin M (IgM) was 0.612 (95% CI, 0.520-0.703). Markers associated with adverse pregnancy outcomes were aD1 (P<.001), anticardiolipin IgG (P<.001), β2-glycoprotein I IgG (P=.003), antiphosphatidylserine-prothrombin IgG (P<.001), antiphosphatidylserine-prothrombin IgM (P=.03), and lupus anticoagulant (P<.001). Backward selection identified lupus anticoagulant, aD1, and antiphosphatidylserine-prothrombin IgG for final adverse pregnancy outcome modeling: lupus anticoagulant odds ratio (OR) 7.0 (95% CI, 3.4-14.4), aD1 OR 12.1 (95% CI, 3.64-40.2), and antiphosphatidylserine-prothrombin IgG OR 11.4 (95% CI, 5.2-25.2). Both aD1 and antiphosphatidylserine-prothrombin IgG remained significant when lupus anticoagulant was removed from the model. Both aD1 and antiphosphatidylserine-prothrombin IgG performed the best in ruling in adverse pregnancy outcomes. With a likelihood ratio less than 0.1, aD1 or antiphosphatidylserine-prothrombin IgG performed well for ruling out adverse pregnancy outcomes. Both aD1 and antiphosphatidylserine-prothrombin IgG were associated with lupus anticoagulant positivity: OR 27.9 (95% CI, 12.1-64.0) if both were positive. Adverse pregnancy outcomes were highest in those with positive lupus anticoagulant, aD1, and antiphosphatidylserine-prothrombin IgG (47.6%). CONCLUSION: In pregnant individuals with aPL, with or without SLE, aD1 and antiphosphatidylserine-prothrombin IgG are significant independent predictors of adverse pregnancy outcomes and are strongly associated with lupus anticoagulant. Combined use may identify patients at greatest risk for severe obstetric complications.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Moyle KA, Branch DW, Peterson LK, et al. Association Between Novel Antiphospholipid Antibodies and Adverse Pregnancy Outcomes. Obstet Gynecol. 2024. PMID: 39666985. doi:10.1097/AOG.0000000000005729

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。